Immuneering Corp
2 nominees · 2 ballot items.
1) Election of two Class II directors (Peter Feinberg and Laurie B. Keating); 2) Ratification of appointment of RSM US LLP as independent registered public accounting firm for fiscal 2026.
Follow how the vote landed and what changed on Immuneering Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect two Class II directors (Peter Feinberg and Laurie B. Keating) to serve three-year terms expiring in 2029.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of RSM US LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
More detail
This management proposal requests that stockholders ratify the audit committee’s appointment of RSM US LLP as Immuneering’s independent registered public accounting firm for fiscal year 2026. Management and the audit committee present this as a routine corporate governance matter — they emphasize that RSM has served since 2020 and that the committee evaluated the firm’s qualifications, technical expertise, audit team, independence, global capabilities, and experience with the company; they note the firm has no disqualifying financial interests. The Board states that ratification is not required but seeks stockholder input as good governance and reserves the right to change auditors if it deems appropriate. For analysts, relevant context includes the disclosed audit and related fees (audit fees of $276,938 and audit-related fees of $168,525 for 2025), the audit committee’s role and independence, and the potential signal if stockholders were to reject ratification (triggering audit committee review). The Board recommends a vote FOR based on oversight of audit quality, cost-benefit considerations, and continuity of financial reporting and controls.
Nominees on the ballot2
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | FMR LLC | 8.8% | 5,707,949 | $30M |
| 2 | FMR LLC | 6.0% | 3,897,279 | $21M |
| 3 | Sanofi | 4.2% | 2,708,559 | $14M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,288,341 | $12M |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.8% | 1,829,188 | $10M |
| 6 | MARSHALL WACE, LLP | 2.7% | 1,719,773 | $9M |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.7% | 1,102,712 | $6M |
| 8 | BlackRock, Inc. | 1.4% | 920,981 | $5M |
| 9 | Occam Crest Management LP | 0.8% | 545,098 | $3M |
| 10 | BlackRock, Inc. | 0.8% | 523,086 | $3M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Immuneering Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Immuneering Corp 2026 annual meeting?
- Immuneering Corp (IMRX) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
- What is the record date for the Immuneering Corp 2026 meeting?
- The record date for the Immuneering Corp 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Immuneering Corp's 2026 meeting?
- The board is presenting 2 director nominees at the Immuneering Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Immuneering Corp 2026 meeting?
- Shareholders will vote on 2 proposals at the Immuneering Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.